RA Capital Management »

Arcellx shares owned by RA Capital Management

Quarter-by-quarter ownership of Arcellx (ACLX) shares owned by RA Capital Management from 13F filings

Historical chart of RA Capital Management investment in Arcellx

Tip: Access up to 7 years of quarterly data

All positions including Arcellx held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arcellx by RA Capital Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $155M 1.9M 83.51
2024-06-30 $89M 1.6M 55.19

More positions owned by RA Capital Management

Ascendis Pharma A/s - SH (ASND)
Vaxcyte SH (PCVX)
Janux Therapeutics SH (JANX)
Legend Biotech Corp- SH (LEGN)
Rhythm Pharmaceuticals SH (RYTM)
Avidity Biosciences SH (RNA)
Tyra Biosciences SH (TYRA)
Evolent Health Inc - A SH (EVH)
Edgewise Therapeutics SH (EWTX)
Biogen SH (BIIB)
Dyne Therapeutics SH (DYN)
Rxsight SH (RXST)
Bicara Therapeutics SH (BCAX)
Climb Bio SH (CLYM)
Ars Pharmaceuticals SH (SPRY)

View all positions for RA Capital Management

Top funds holding Arcellx

FMR
Paradigm Biocapital Advisors
BlackRock
Perceptive Advisors
NEA Management Company
Vanguard Group
Sr One Capital Management
Henderson Group
T. Rowe Price Associates
RA Capital Management
State Street Corporation
Cormorant Asset Management
Susquehanna International
Geode Capital Management
T. Rowe Price Investment Management

View all funds holding Arcellx